Elvia Cowan - 29 Aug 2025 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Role
SVP, FINANCE
Signature
Elvia Cowan, by /s/ Peter N. Efremenko, Attorney-In-Fact
Issuer symbol
PCVX
Transactions as of
29 Aug 2025
Net transactions value
$0
Form type
4
Filing time
29 Aug 2025, 20:08:15 UTC
Previous filing
03 Mar 2025
Next filing
04 Sep 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Cowan Elvia SVP, FINANCE C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, SUITE 300, SAN CARLOS Elvia Cowan, by /s/ Peter N. Efremenko, Attorney-In-Fact 29 Aug 2025 0001960048

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCVX Common Stock Award $0 +2,810 +12% $0.000000 27,205 07 Sep 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCVX Stock Option (right to buy) Award $0 +9,743 $0.000000 9,743 29 Aug 2025 Common Stock 9,743 $30.79 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 25% of the shares subject to the award on March 7, 2026 and 12.5% of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.
F2 Includes 289 shares acquired under the Issuer's Employee Stock Purchase Plan on May 16, 2025.
F3 1/48 of shares subject to the option vest on September 29, 2025, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.